What is William Blair’s Estimate for argenx FY2026 Earnings?

argenx SE (NASDAQ:ARGX) – Equities researchers at William Blair increased their FY2026 earnings per share (EPS) estimates for shares of argenx in a note issued to investors on Friday, February 28th. William Blair analyst M. Minter now anticipates that the company will earn $26.61 per share for the year, up from their previous estimate of $26.08. William Blair currently has a “Outperform” rating on the stock. The consensus estimate for argenx’s current full-year earnings is $3.13 per share. William Blair also issued estimates for argenx’s FY2027 earnings at $28.62 EPS and FY2028 earnings at $40.92 EPS.

A number of other equities analysts have also commented on the stock. Evercore ISI boosted their price target on shares of argenx from $675.00 to $706.00 and gave the company an “outperform” rating in a research report on Thursday, November 21st. Wolfe Research upgraded shares of argenx from a “peer perform” rating to an “outperform” rating and set a $697.00 target price for the company in a research note on Tuesday, November 12th. Scotiabank upgraded argenx from a “sector perform” rating to a “sector outperform” rating and increased their price target for the stock from $439.00 to $715.00 in a research report on Tuesday, November 5th. Wedbush reaffirmed an “outperform” rating and set a $655.00 price target on shares of argenx in a report on Tuesday, December 3rd. Finally, Oppenheimer boosted their price objective on argenx from $675.00 to $704.00 and gave the stock an “outperform” rating in a research note on Friday. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating, eighteen have issued a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, argenx presently has an average rating of “Moderate Buy” and an average target price of $661.17.

argenx Stock Performance

ARGX opened at $622.61 on Monday. The firm has a market cap of $37.83 billion, a price-to-earnings ratio of -707.51 and a beta of 0.58. The firm’s 50-day simple moving average is $642.62 and its 200-day simple moving average is $591.22. argenx has a twelve month low of $349.86 and a twelve month high of $678.21.

argenx (NASDAQ:ARGX) last announced its quarterly earnings results on Thursday, February 27th. The company reported $1.58 earnings per share for the quarter, beating analysts’ consensus estimates of $0.98 by $0.60. The firm had revenue of $761.22 million for the quarter, compared to analysts’ expectations of $678.52 million. argenx had a negative return on equity of 1.45% and a negative net margin of 2.11%.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of ARGX. GeoWealth Management LLC raised its stake in shares of argenx by 56.3% during the fourth quarter. GeoWealth Management LLC now owns 50 shares of the company’s stock worth $31,000 after buying an additional 18 shares during the last quarter. Steward Partners Investment Advisory LLC raised its position in shares of argenx by 5.6% during the 4th quarter. Steward Partners Investment Advisory LLC now owns 380 shares of the company’s stock valued at $234,000 after acquiring an additional 20 shares during the last quarter. SG Americas Securities LLC raised its position in shares of argenx by 6.2% during the 4th quarter. SG Americas Securities LLC now owns 358 shares of the company’s stock valued at $220,000 after acquiring an additional 21 shares during the last quarter. Farther Finance Advisors LLC lifted its stake in shares of argenx by 38.2% in the 4th quarter. Farther Finance Advisors LLC now owns 76 shares of the company’s stock valued at $47,000 after purchasing an additional 21 shares during the period. Finally, Dynasty Wealth Management LLC boosted its position in shares of argenx by 3.4% in the 4th quarter. Dynasty Wealth Management LLC now owns 677 shares of the company’s stock worth $416,000 after purchasing an additional 22 shares during the last quarter. Institutional investors own 60.32% of the company’s stock.

argenx Company Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.